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Background:UC is platinum-responsive and hypothesized to be sensitive to targeted
DNA-damaging agents such as PARP inhibitors (PARPi). Cisplatin (cis)-ineligible pts
with metastatic/unresectable primary UC have limited effective treatment options.
Immune checkpoint blockade may increase the proportion of pts that respond to
PARPi. Durvalumab is a selective, high-affinity, engineered, human IgG1monoclonal
Ab that blocks PD-L1 binding to PD-1 and CD80. In UC, the combination of olaparib
(a PARPi)þ durvalumabmay broaden the therapeutic effect of monotherapy given
their different mechanisms of action, with potentially enhanced benefit for pts with
metastatic/unresectable UC and DNA repair deficiencies (mutations in homologous
recombination repair genes [HRRm]).
Trial design: BAYOU is a double-blind, randomized, placebo-controlled, multicenter
phase 2 study designed to assess the efficacy and safety of durvalumabþ olaparib vs
durvalumabþ placebo in cis-ineligible pts with stage IV UC. Adult pts (18 years)
who are cis-ineligible with histologically/cytologically confirmed unresectable stage IV
UC,WHO performance status 0-2, and with knownHRRm status will be enrolled. Pts
with active/prior autoimmune disorders, brain metastases, prior PARPi/immune ther-
apy, current/prior immunosuppressive agents, non-UC invasive malignancies, and
concomitant use of strong CYP3A inhibitors/inducers are excluded. All pts will be
randomized (1:1) to durvalumab (1500mg intravenous, every 4 weeks)þ placebo or
durvalumabþ olaparib (tablet) until disease progression. Olaparib dose will be 300mg
twice daily in pts with CrCl>50mL/min and 200mg twice daily in pts with CrCl31
to 50mL/min. The primary endpoint is progression-free survival in HRRm patients
(investigator assessed, RECIST v1.1). Secondary endpoints are overall survival (OS),
duration of response, objective response rate, proportion of pts alive and progression
free at 6months, and OS at 18months. Safety, pharmacokinetics, and immunogenicity
will also be assessed. The trial is currently enrolling pts.
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Background: Long-term survival is poor for patients with locally advanced or meta-
static urothelial carcinoma (UC) receiving chemotherapy and/or immunotherapy fol-
lowing progression with platinum-containing chemotherapy. Genetic alterations of
fibroblast growth factor receptors (FGFR) have been shown to play a role in UC devel-
opment and progression. Non-genetic and epigenetic activation of FGFR gene expres-
sion have also been described. Rogaratinib, an oral pan-FGFR 1-3 inhibitor, has shown
promising activity and a manageable safety profile in a phase I study in patients with
UCwho were selected based on FGFR1-3mRNA overexpression and/or activating
mutations in the FGFR3 gene.
Trial design: This is a randomized, open-label, phase 2/3 study to evaluate the efficacy
and safety of rogaratinib compared to chemotherapy in patients with FGFR-positive
locally advanced or metastatic UC who have received prior platinum-containing che-
motherapy. The primary objective is to show superiority of rogaratinib over
chemotherapy in prolonging overall survival (OS) of UC patients with FGFR-positive
tumors. Secondary objectives include: objective response rate (ORR), progression-free
survival, disease control rate, duration of response, and safety. Testing for FGFR1 and 3
mRNA over expression will be conducted centrally using an RNA in situ hybridization
(RNA-ISH) in archival samples. Eligible patients will be randomized 1:1 to rogaratinib
(800mg po bid) or iv chemotherapy Q3W (docetaxel 75mg/m2; paclitaxel 175mg/m2;
or 320mg/m2 vinflunine). Randomization will be stratified according to PIK3CA and/
or RAS activating mutations, prior immunotherapy, andmodified 4-factor Bellmunt
risk score. The objective for the phase 2 part of the study is ORR. A total of 116 patients
in PIK3CA and RASWT patients will be enrolled to the phase 2 part of the study to rule
out a low difference in ORR between rogaratinib and chemotherapy as futility. The
phase 3 portion of the study is powered to detect an increase in median OS in PIK3CA
and RASWT patients. Total patient enrollment expected to be approximately 400
patients.
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Background: Initial results from the CheckMate 214 randomised phase III study dem-
onstrate an overall survival advantage for combination ipilimumab plus nivolumab
over sunitinib in front-line treatment of patients with intermediate/poor risk meta-
static renal cell carcinoma (mRCC). However, the safety profile of nivolumab-plus-ipi-
limumab could be further optimised: 46% (250/547) of patients experienced a Grade 3-
4 adverse reaction (AR), 22% (118/547) discontinued therapy due to ARs and (35%)
(152/436) patients needed high dose steroids to resolve immune-mediated ARs. The
aim of the PRISM trial is to explore safer and more tolerable scheduling of these agents.
We hypothesise that 12-weekly rather than standard 3-weekly dosing of ipilimumab, in
combination with nivolumab, will result in lower rates of grade 3-4 ARs whilst main-
taining treatment efficacy.
Trial design: PRISM is a multi-centre phase II trial randomising patients (1:2) to nivo-
lumab 3mg/kg combined with ipilimumab 1mg/kg every 3 weeks for 4 doses, followed
by nivolumab 240mg flat-dose every 2 weeks (standard arm) versus nivolumab 3mg/kg
combined with ipilimumab 1mg/kg at weeks 1, 13, 25 & 37 (4 doses) with single-agent
2-weekly nivolumab 240mg given in intervening weeks (experimental arm). Patients
with untreated metastatic clear cell RCC will form the study population and patients
with good, intermediate and poor prognosis disease, as per IMDC criteria, are eligible.
The primary endpoint of the study is the rate of grade 3 or 4 ARs within the initial 12
months of treatment. Progression-free survival (PFS) at 12 months forms a key secon-
dary endpoint, to exclude the PFS rate of no interest and support further investigation
in a subsequent definitive phase III trial. Other secondary endpoints include treatment
discontinuation rates, quality of life, overall response rate and duration of response. An
exploratory objective is to examine circulating and tissue-based biomarkers of
response. The study aims to recruit 189 patients across 15 UK centres over a 2-year
period and opened inMarch 2018. To date, 4 patients have been recruited.
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